Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment
Posted on 17 Nov 2026
Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable tumor alterations, highlighting the value of broader molecular profiling before treatment. A new study suggests that broad-based genomic sequencing before first-line therapy is associated with longer survival, supporting its potential role in guiding treatment decisions.
Researchers at Emory University School of Medicine and Winship Cancer Institute evaluated the impact of broad-based genomic sequencing on treatment outcomes in patients with advanced non-small cell lung cancer. Unlike limited testing that examines only one or two biomarkers, broad-based sequencing analyzes dozens or hundreds of genes simultaneously, potentially identifying a wider range of actionable tumor alterations to guide targeted therapy selection.
The study analyzed real-world data from the Flatiron Health Research Database, including more than 35,000 patients treated at community and academic oncology practices across the United States between 2016 and 2022. Researchers compared outcomes among patients who underwent broad-based genomic sequencing before first-line treatment with those who received more limited biomarker testing.
Patients who underwent broad-based genomic sequencing before first-line therapy had an average overall survival approximately two months longer than those receiving limited testing. The approach was also associated with modest improvements in progression-free survival. Additionally, 19% of patients in the broad-based sequencing group received targeted therapy, compared with 16% in the limited testing group. The findings were published in the November 2026 issue of the Journal of the National Comprehensive Cancer Network.
The results support existing National Comprehensive Cancer Network (NCCN) guidelines recommending broad-based genomic sequencing for patients with advanced or metastatic non-small cell lung cancer. Relevant biomarkers include EGFR, ALK, ROS1, KRAS G12C, MET, RET, and BRAF, which can help identify patients eligible for targeted treatments. The findings, also discussed in commentary from City of Hope, highlight the potential clinical value of comprehensive molecular profiling before treatment initiation.
“Our findings and prior work suggest broad-based genomic testing should be the default for patients with advanced lung cancer and should ideally happen prior to the administration of first-line therapy. The right test, done early, can open doors to treatments that might otherwise be missed,” said Ravi B. Parikh, M.D., M.P.P., of Emory University School of Medicine and Winship Cancer Institute.
Related Links
Emory University School of Medicine
Winship Cancer Institute